Yaky Yanay at Dubai conference: They put Israel on the map as an island of innovation
Pluristem's PLX-R18 aims to stimulate the regenerative potential of the bone marrow to enhance the production of all three blood cell lineages: hemoglobin, neutrophil and platelet counts.
The committee is composed of five prominent infectious diseases, critical care, internal medicine and pumonology specialists from around the world
"We have so far found no negative side effects from the use of the PLX-PAD cells in the treatment of steroid-refractory cGvHD."
The Israeli-Emirati joint projects aim to utilize each company's strengths in order to achieve results that will integrate the expertise of both companies.
More coronavirus patients who do not qualify for the company’s clinical trial will now be able to receive treatment
“We see cell therapy and gene editing as highly synergistic methods to treat and cure diseases using advanced technologies."
The survival rate is 87.5%, Pluristem Therapeutics reported.
Six critically ill coronavirus patients in Israel who were considered high-risk for mortality were treated with Pluristem and survived.
The financing is backed by a guarantee from the European Fund for Strategic Investments (EFSI), the financial pillar of the European Union's Investment Plan for Europe.
JPOST Digital Library
